Adam Mossoff
Biographic Data
| ID | 7143533 |
|---|---|
| NAME | Adam Mossoff |
| GIVEN NAMES | Adam |
| FAMILY NAME | Mossoff |
| SIGNATURE | MOSSOFF A |
| AFFILIATIONS | George Mason University, Arlington, VA, USA |
| ORCID | 0000-0001-6962-1129 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Patents as a Driver of the Unprecedented Biomedical Response to Covid-19
The response by the biotech and pharmaceutical sectors to the COVID-19 pandemic has been historically unprecedented. Vaccines based in cutting-edge technologies, such as the mRNA platform, were invented, tested, and distributed to patients in less than a year. Yet politicians and activists argue that patents and other intellectual property (IP) have impeded the development and distribution of these vaccines. In explaining why this is profoundly m…
Patent Injunctions, Economics, and Rights
Richard Epstein has long defended classical liberalism, property rights, and private ordering, including the presumption that a patent owner deserves an injunction against ongoing infringement. We agree with Epstein that injunctions should be a presumptive remedy for infringement, but we have reservations about his consequentialist, law and economics justification for this position. Law and economics justifications struggle to explain why the sta…
No prominent works on this page.
Patent Injunctions, Economics, and Rights
Richard Epstein has long defended classical liberalism, property rights, and private ordering, including the presumption that a patent owner deserves an injunction against ongoing infringement. We agree with Epstein that injunctions should be a presumptive remedy for infringement, but we have reservations about his consequentialist, law and economics justification for this position. Law and economics justifications struggle to explain why the sta…
Patents as a Driver of the Unprecedented Biomedical Response to Covid-19
The response by the biotech and pharmaceutical sectors to the COVID-19 pandemic has been historically unprecedented. Vaccines based in cutting-edge technologies, such as the mRNA platform, were invented, tested, and distributed to patients in less than a year. Yet politicians and activists argue that patents and other intellectual property (IP) have impeded the development and distribution of these vaccines. In explaining why this is profoundly m…
Political science (2 works) · 2019-20 coronavirus outbreak (1 work) · Biomedical and Engineering Education (1 work) · Biomedical Ethics and Regulation (1 work) · Classical liberalism (1 work) · Coercion (linguistics) (1 work) · Coronavirus disease 2019 (COVID-19 (1 work) · Coronavirus Infections (1 work) · Crisis response (1 work) · Economics (1 work)